Immunogen news.

AbbVie Pays $10.1 Billion for ImmunoGen to Expand Its Cancer Drug Portfolio. Get the latest ImmunoGen, Inc. (IMGN) stock news and headlines to help you in your trading and investing decisions. ImmunoGen (IMGN) Barclays analyst Peter Lawson maintained a Buy rating on ImmunoGen yesterday and set a price target of $20.00 . The company’s shares closed last Thursday at $18.70, close to its ...November 30, 2023 at 7:45 AM · 1 min read. (Reuters) — AbbVie said on Thursday it will buy ImmunoGen for $10.1 billion, underscoring a growing interest from large drugmakers in a promising ...The company said it will pay $31.26 in cash for each ImmunoGen share. That amounts to a 95% premium on the stock's closing closing price Wednesday of $16.06. The deal delivers Elahere, an ImmunoGen ovarian cancer treatment that AbbVie says could eventually reap billions of dollars in annual sales and drive long-term revenue growth.

The FDA granted accelerated approval for ImmunoGen Inc's (NASDAQ:IMGN) Elahere (mirvetuximab soravtansine-gynx) for folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian ...Shares of ImmunoGen spiked in response to this news, closing up 82.8%. Clearly, for its investors, this was a fantastic development that created significant amounts of shareholder value instantly.

A U.S. appeals court on Friday revived a lawsuit brought by biotech company ImmunoGen Inc in an attempt to secure a patent related to its planned ovarian cancer treatment. ... the news and media ...ImmunoGen shares have rocketed 83% to over $29 per share on the news. Reacting to the report, analysts at BMP Capital said they view today's news as a positive for their SMID cap coverage, particularly names with important 2024 de-risking events.5 days ago ... Ropes & Gray advised ImmunoGen in the deal that Bloomberg News said is aimed at gaining access to come of the hottest new drugs in the growing ...AbbVie (NYSE:ABBV) agreed to acquire ImmunoGen (NASDAQ:IMGN), a developer of a new class of cancer drugs called antibody-drug conjugates ((ADCs)), on Thursday for $10.1B in cash, lifting the ...Get the latest ImmunoGen Inc. (IMGN) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.

In the last 3 months, 4 analysts have offered 12-month price targets for Immunogen. The company has an average price target of $23.25 with a high of $28.00 and a low of $16.00.

16-Nov-2022 ... ImmunoGen ELAHERE wins accelerated FDA approval for ovarian cancer. News. ImmunoGen_logo. ImmunoGen, Inc. has announced that its platinum ...

In the last 3 months, 4 analysts have offered 12-month price targets for Immunogen. The company has an average price target of $23.25 with a high of $28.00 and a low of $16.00.A press release from AbbVie reveals that ImmunoGen is being acquired for $31.26 per share in cash. This is a roughly 94.6% premium over its prior closing price. It also represents a total value of ...Nov 30, 2023 · Some statements in this news release, including those relating to the proposed acquisition of ImmunoGen by AbbVie, are, or may be considered, forward-looking statements. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. 4 days ago ... STATEMENT RE IMMUNOGEN, INC. 07:00:10 30 Nov 2023 - BIOPHARMA CREDIT PLC - News article - Regulatory News Service.Nov 28, 2023 · A high-level overview of ImmunoGen, Inc. (IMGN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. View the latest Immunogen Inc. (IMGN) stock price, news, historical charts, analyst ratings and financial information from WSJ.Get the latest ImmunoGen, Inc. (IMGN) real-time quote, historical performance, charts, and other financial information to help you make more informed ...

Nov 30, 2023 · The need-to-know this morning. • Abbvie said it would acquire ImmunoGen, a maker of cancer drugs, for $10.1 billion. ImmunoGen is being acquired for $31.26 per share, or a 95% premium to its ... When ImmunoGen last reported its balance sheet in September 2022, it had zero debt and cash worth US$310m. Importantly, its cash burn was US$217m over the trailing twelve months. Therefore, from ...ImmunoGen shares jump 7% premarket on news of license deal with Lilly worth up to $1.7 billion ImmunoGen Inc. shares jumped 7% in premarket trade Tuesday, after the company announced a license ... AbbVie Inc. (NYSE: ABBV) and ImmunoGen, Inc. (NASDAQ: IMGN) today announced a definitive agreement under which AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE ...RTTNews Nov. 30, 2023, 07:49 AM (RTTNews) - AbbVie Inc. (ABBV) and ImmunoGen, Inc. (IMGN) announced Thursday AbbVie will acquire ImmunoGen, and its flagship …MEDIA ImmunoGen Courtney O'Konek 781-895-0600 [email protected] OR FTI Consulting Robert Stanislaro 212-850-5657 [email protected] Last Week: ImmunoGen Boosts Annual Guidance On Upbeat Uptake Of Newly Approved Ovarian Cancer Drug IMGN Price Action: ImmunoGen shares were up 93.5% at $10.06 at time of publication ...

Weighted average shares outstanding increased to 253.5 million for the 2022 period from 204.8 million in the prior year. ImmunoGen had $309.5 million in cash and …

Shares of Immunogen are trading down 2.6% over the last 24 hours, at $14.97 per share. A move to $18.00 would account for a 20.24% increase from the current share price. About Immunogen05-Jun-2023 ... ... Immunogen, ovarian cancer, Women's Health. Hear the latest industry news first. Sign up for our daily newsletter. We will never sell or share ...WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 4, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2022.Nov 30, 2023 · More Thursday Stock Market News. QS Stock Alert: Truist Just Gave QuantumScape a Price Target Boost; Why Is ImmunoGen (IMGN) Stock Up 81% Today? HOOD Stock Alert: Robinhood Launches in the U.K. May 9, 2023 · WALTHAM, Mass., May 09, 2023--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the closing of its ... In other ImmunoGen news, SVP Stacy Ann Coen sold 100,210 shares of the stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $14.20, for a total ...

ImmunoGen names Renee Lentini interim CFO as Susan Altschuller on medical leave. Get the latest news and real-time alerts from ImmunoGen, Inc. (IMGN) …

Nov 30, 2023 · Chicago-based AbbVie Inc. (NYSE: ABBV) will spend about $10.1 billion to acquire ImmunoGen Inc. (Nasdaq: IMGN), the companies announced Thursday. The deal values each ImmunoGen share at $31.26 ...

Reuters. (Reuters) -AbbVie said on Thursday it will buy ImmunoGen for $10.1 billion, underscoring a growing interest from large drugmakers in a promising class of targeted cancer therapies. Through the deal, AbbVie gains Elahere that is approved for ovarian cancer patients who have received previous therapies, and is also being tested in ...Net loss for the year ended December 31, 2022 was $222.9 million, or $0.88 per diluted share, compared to a net loss of $139.3 million, or $0.68 per diluted share, for the year ended December 31 ...16-Nov-2022 ... ImmunoGen ELAHERE wins accelerated FDA approval for ovarian cancer. News. ImmunoGen_logo. ImmunoGen, Inc. has announced that its platinum ...(RTTNews) - ImmunoGen Inc. (IMGN) announced full results from the pivotal SORAYA trial evaluating the efficacy and safety of mirvetuximab soravtansine (mirvetuximab) monotherapy in patients with ...WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 4, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2022.Nov 30, 2023 · AbbVie and ImmunoGen said Thursday that the boards of both companies have approved the transaction. It’s expected to close in the middle of 2024. It still needs approval from ImmunoGen shareholders and regulators. Shares of Waltham, Massachusetts.-based ImmunoGen Inc. soared more than 80% to top $29 in mid-morning trading Thursday. Find the latest news headlines from ImmunoGen, Inc. Common Stock (IMGN) at Nasdaq.com.ImmunoGen ( NASDAQ: IMGN) jumped 12% on speculation that the biotech firm may be a takeover target. There's some speculation that a large European …ImmunoGen (IMGN) H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on ImmunoGen today and set a price target of $27.00 . The company’s shares closed last Monday at $15.54.What's going on at ImmunoGen (NASDAQ:IMGN)? Read today's IMGN news from trusted media outlets at MarketBeat.The Dow Jones industrials index hit its highest level in 2023 on Thursday, as Salesforce jumped on an upbeat profit forecast and a new report offered further evidence of easing inflation. At 10:37 ET, the Dow Jones Industrial Average DJI was up 0.82% at 35,720.74. The S&P 500 SPX was up 0.07% at 4,553.57 and the Nasdaq Composite …

INVESTOR RELATIONS CONTACT ImmunoGen Anabel Chan 781-895-0600 [email protected] MEDIA CONTACTS ImmunoGen Courtney O’Konek 781-895-0600 [email protected] OR FTI Consulting ...By Leroy Leo and Manas Mishra (Reuters) -AbbVie will buy ImmunoGen (NASDAQ: IMGN) for $10.1 billion in cash, it said on Thursday, the latest major drugmaker to acquire a maker of promising "guided ...Nov 30, 2023 · Photo: Brian L. Frank for The Wall Street Journal. Drug company AbbVie has agreed to buy biotech ImmunoGen for $10.1 billion in a new bet on one of the most promising novel drug technologies for ... Instagram:https://instagram. financial advisors wichita ksdangerous trends on social mediabest family dentalcigna discount dental plan ImmunoGen (IMGN) H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on ImmunoGen today and set a price target of $27.00 . The company’s shares closed last Monday at $15.54. computer science tutoring onlinebest stock to swing trade AbbVie is buying ImmunoGen in a deal valued at about $10.1 billion with the goal of speeding the pharmaceutical’s entry into the market for ovarian cancer treatments. ImmunoGen Inc. developed the ovarian cancer drug Elahere, which AbbVie says it sees as a potential multibillion-dollar future revenue generator. “The acquisition of ImmunoGen …May 4, 2023 · ImmunoGen reported a net loss of $41.0 million for the quarter. As of March 31, 2023, the company had $201.2 million in cash and cash equivalents, with operational cash usage of $73.7 million. usa stock dividend 16-Nov-2022 ... ImmunoGen ELAHERE wins accelerated FDA approval for ovarian cancer. News. ImmunoGen_logo. ImmunoGen, Inc. has announced that its platinum ...May 3 (Reuters) - ImmunoGen Inc (IMGN.O) shares more than doubled on Wednesday after the company said its experimental ovarian cancer drug helped extend …